In the first nine months of 1994, Ciba of Switzerland's sales were 16.6 billion Swiss francs ($12.9 billion), down 3% in Swiss franc terms but ahead 3% in local currencies.
The company said that the third-quarter performance was consistent with that of the first half-year. However, due to the weakening of almost all important currencies against the Swiss franc, the sales were down.
The health care sector achieved nine-month sales of 6.4 billion francs, down 4%, but with 1% growth when expressed in local currency terms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze